It has been shown that the levels of AMPK activation are substantially decreased in animals and patients with NAFLD, whereas the activation of AMPK by genetic manipulation, exercise, activators (e.g., A-769662, EX229/991, MT47-100), and mitochondria inhibitors (e.g., metformin) showed protective effects [12,13,14,15,16,17]. Here, PRKAB1 is linked to metabolic dysfunction-associated steatotic liver disease.